HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 POL GENE-MUTATIONS IN AN AIDS PATIENT TREATED WITH MULTIPLE ANTIRETROVIRAL DRUGS

被引:33
作者
FITZGIBBON, JE
FARNHAM, AE
SPERBER, SJ
KIM, H
DUBIN, DT
机构
[1] UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT MED,NEW BRUNSWICK,NJ 08903
[2] UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT MED,DIV HEMATOL & ONCOL,NEW BRUNSWICK,NJ 08903
关键词
D O I
10.1128/JVI.67.12.7271-7275.1993
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Multiple mutations were found in the human immunodeficiency virus pol gene following treatment of an AIDS patient with antiretroviral drugs. After approximately 2.5 years of monthly alternating therapy with 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (ddC), most of the pol sequences amplified from the patient's peripheral blood mononuclear cell DNA contained known AZT resistance mutations at codons 41, 67, and 215 and a putative ddC resistance mutation at codon 69 as well as other novel mutations. These mutations persisted for 6 months after the patient was switched to 2',3'-dideoxyinosine monotherapy. Mutations known to be associated with 2',3'-dideoxyinosine resistance did not occur during this time. Antiviral susceptibility testing of point mutants, introduced into the genetic background of laboratory strain NL4-3, showed that the codon 41 mutation antagonized ddC resistance when present with the codon 69 mutation. However, this antagonism was not found with a chimeric mutant containing the patient's pol gene sequence from codons 25 to 218, implying that other mutations compensated for the antagonism. Thus, alternating therapy with AZT and ddC resulted in the selection of viruses resistant to both drugs.
引用
收藏
页码:7271 / 7275
页数:5
相关论文
共 31 条
[1]   ZIDOVUDINE SENSITIVITY OF HUMAN IMMUNODEFICIENCY VIRUSES FROM HIGH-RISK, SYMPTOM-FREE INDIVIDUALS DURING THERAPY [J].
BOUCHER, CAB ;
TERSMETTE, M ;
LANGE, JMA ;
KELLAM, P ;
DEGOEDE, REY ;
MULDER, JW ;
DARBY, G ;
GOUDSMIT, J ;
LARDER, BA .
LANCET, 1990, 336 (8715) :585-590
[2]   A COMPREHENSIVE SET OF SEQUENCE-ANALYSIS PROGRAMS FOR THE VAX [J].
DEVEREUX, J ;
HAEBERLI, P ;
SMITHIES, O .
NUCLEIC ACIDS RESEARCH, 1984, 12 (01) :387-395
[3]  
FISCHL MA, 1989, JAMA-J AM MED ASSOC, V262, P2405
[4]   THE EFFICACY OF AZIDOTHYMIDINE (AZT) IN THE TREATMENT OF PATIENTS WITH AIDS AND AIDS-RELATED COMPLEX - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
FISCHL, MA ;
RICHMAN, DD ;
GRIECO, MH ;
GOTTLIEB, MS ;
VOLBERDING, PA ;
LASKIN, OL ;
LEEDOM, JM ;
GROOPMAN, JE ;
MILDVAN, D ;
SCHOOLEY, RT ;
JACKSON, GG ;
DURACK, DT ;
KING, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (04) :185-191
[5]  
FITZGIBBON J, 1992, 32ND INT C ANT AG CH
[6]   HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 POL GENE-MUTATIONS WHICH CAUSE DECREASED SUSCEPTIBILITY TO 2',3'-DIDEOXYCYTIDINE [J].
FITZGIBBON, JE ;
HOWELL, RM ;
HABERZETTL, CA ;
SPERBER, SJ ;
GOCKE, DJ ;
DUBIN, DT .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (01) :153-157
[7]   INVIVO PREVALENCE OF AZIDOTHYMIDINE (AZT) RESISTANCE MUTATIONS IN AN AIDS PATIENT BEFORE AND AFTER AZT THERAPY [J].
FITZGIBBON, JE ;
HOWELL, RM ;
SCHWARTZER, TA ;
GOCKE, DJ ;
DUBIN, DT .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1991, 7 (03) :265-269
[8]   NOVEL MUTATION IN THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE GENE THAT ENCODES CROSS-RESISTANCE TO 2',3'-DIDEOXYINOSINE AND 2',3'-DIDEOXYCYTIDINE [J].
GU, ZX ;
QING, G ;
LI, XG ;
PARNIAK, MA ;
WAINBERG, MA .
JOURNAL OF VIROLOGY, 1992, 66 (12) :7128-7135
[9]   SITE-DIRECTED MUTAGENESIS BY OVERLAP EXTENSION USING THE POLYMERASE CHAIN-REACTION [J].
HO, SN ;
HUNT, HD ;
HORTON, RM ;
PULLEN, JK ;
PEASE, LR .
GENE, 1989, 77 (01) :51-59
[10]   5TH MUTATION IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE CONTRIBUTES TO THE DEVELOPMENT OF HIGH-LEVEL RESISTANCE TO ZIDOVUDINE [J].
KELLAM, P ;
BOUCHER, CAB ;
LARDER, BA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (05) :1934-1938